Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

European Journal of Cancer(2024)10.1016/j.ejca.2024.114241Source: DataRank Database

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615) is a research paper published in European Journal of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.30)OA: bronzeTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Joel M. Reid ORCID,Charles G. Minard ORCID,Sarah E. Woodfield ORCID,Kristina Z. Denic,Emasenyie Isikwei ORCID

Live enrichment

PubMed:39096851 PMC:PMC11392690 OpenAlex:https://openalex.org/W4401244864

NIGMS NIH HHS

Grant: T32 GM008685

NCI NIH HHS

Grant: R50 CA275928

NCI NIH HHS

Grant: P30 CA015083

NCI NIH HHS

Grant: UM1 CA228823

FWCI

2.30

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.ejcancer.com/article/S0959-8049(24)00897-9/pdf

publisherhttps://www.ejcancer.com/article/S0959-8049(24)00897-9/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0959804924008979?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0959804924008979?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ejca.2024.114241

Fields of Study

Ubiquitin and proteasome pathwaysATP Synthase and ATPases ResearchCancer-related Molecular Pathways

MeSH Terms

NEDD8 ProteinIrinotecanTemozolomideAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCyclopentanesFemaleHumansMaleNeoplasm Recurrence, LocalNeoplasmsPyrimidinesDrug Resistance, NeoplasmMaximum Tolerated DoseYoung Adult

Keywords

Refractory (planetary science)ChemotherapyMedicineSolid tumorCancer researchPhase (matter)OncologyInternal medicineMaterials scienceChemistryCancerMetallurgyOrganic chemistrySarcomaDrug DevelopmentCns TumorsPhase 1Pediatric Oncology

Sustainable Development Goals

SDG 0: Good health and well-being

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

FAIR Checklist

Authors (12)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)